Migraine relieved within 1 hour, FDA approves new oral medication
2020-03-01
2020.02.27, Biohaven announced that the US FDA has approved the company's CGRP receptor inhibitor Nurtec (rimegepant) orally disintegrating tablets (ODT) for the acute treatment of migraine attacks in adults. This is the first small molecule CGRP receptor antagonist with a rapid oral disintegration tablet type. A single piece of Nurtec ODT allows patients to return to normal function within an hour, with a maximum curative effect of up to 48 hours.
